Comparison on the key features of COVID-19 vaccines licensed in the KCDC
Platform | mRNA | Viral vector | |||
---|---|---|---|---|---|
Manufacturer | Pfizer BioNTech | Moderna | Oxford AstraZeneca | Janssen (J&J) | |
Vaccine name | Comirnaty Inj. | Moderna Covid-19 Vaccine Inj. | Astra Zeneca Covid-19 Vaccine Inj. | Covid-19 Vaccine Janssen Inj. | |
Age group | 12 y and above | 18 y and above | 18 y and above | 18 y and above | |
Vial | Multiple dose vial | Multiple dose vial | Multiple dose vial | Multiple dose vial | |
Dose and frequency | 2 doses, 21 days apart | 2 doses, 28 days apart | 2 doses, 4–12 weeks | 1 dose | |
Dosage and route of administration | Diluted vaccine 0.3 mL Intramuscular injection |
0.5 mL Intramuscular injection |
0.5 mL Intramuscular injection |
0.5 mL Intramuscular injection |
|
Cold chain requirements | -90°C to -60°C (6 months) | -25°C to 15°C (7 months) | 2°C to 8°C (6 months) | -25°C to -15°C (24 months) | |
Storage requirements | -90°C to -60°C (6 months) 2°C to 8°C (5 days) |
2°C to 8°C (30 days) | 2°C to 8°C (6 months) | 2°C to 8°C (3 months) | |
Punctured vial and shelf life | After dilution Up to 25°C Within 6 hours |
Up to 25°C Within 6 hours |
Up to 30°C Within 6 hours |
2°C to 8°C Within 6 hours |
|
Up to 25°C Within 3 hours |
Adapted from the article of Korea Disease Control and Prevention Agency.2)
COVID-19, coronavirus disease 2019; KCDC, Korean Centers for Disease Control; Inj, injection.